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Smmmary In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with advanced non-small-cell lung cancer (NSCLC) with the new semisynthetic taxoid docetaxel (Taxoteret) . Six patients were ineligible; of the 37 eligible patients, ten had prior radiotherapy and 18 prior surgery. They received 00mg m2 in 1 h i.v. every 3 weeks, usually in an outpatient setting. Prophylactic steroids, antihistaminics or antiemetics were not routinely given. Two patients were not evaluable because they withdrew from the study because of a hypersensitivity reaction after the second cycle. The main toxicity was neutropenia (80% of cycles), although infections were rare (4%). One patient died from sepsis during neutropenia. Hypersensitivity reactions necessitating interruption of docetaxel (Taxotere) (Cohen & Perevodchikova, 1979; Joss et al., 1984; Hansen et al., 1991) . Data suitable for analysis indicate that, by current standards, response rates to single agents range from 5 to 20%. Detection of new and active agents for the treatment of NSCLC therefore requires the continuing evaluation of novel substances in carefully selected patients with a good prognosis and measurable disease.
In the late 1960s the National Cancer Institute's large-scale plant screening programme found that a crude extract of the bark from the Pacific yew, Taxus brevifolia, has activity against P388 mouse leukaemia. In 1971, Paclitaxel (taxol) was isolated and characterised as the active principle of the extract (Wani et al., 1971) . Docetaxel (Taxotere') is a semisynthetic taxoid which has been synthesised from a precursor extracted from a renewable natural source, the needles of the European yew, Taxus baccata. It enhances microtubule assembly and inhibits the depolymerisation of tubulin. Docetaxel (Taxotere'l) had a favourable activity profile when compared with taxol in animal models (Verweij et al., 1994) , and has therefore been selected for further testing in human clinical trials.
We have conducted a prospective multicentre phase II trial in order to determine the objective response rate and response duration of docetaxel (Taxotere') in patients with advanced NSCLC.
Paient and methods
Patients (see Table I The toxicity was graded using the NCI common toxicity criteria (CTC).
Responses were classified according to the standard WHO criteria. Assignment to the progression category was done 6 weeks after entry into the study. When progression was observed between 3 and 6 weeks after entry into the study, the patient was considered to be undergoing 'early progression'. Progression could not be defined prior to 3 weeks (one full cycle) after entry into the study; patients removed from the study at earlier times for whatever reason were considered non-evaluable for response. (1994), 70, 384-387 (C) Macmillan Press Ltd., 1994 Guidelines for modification of the administration of docetaxel in the cases of hypersensitivity reactions were as follows. For mild symptoms, i.e. localised cutaneous reaction, pruritus or flushing, the rate of infusion was to be decreased until disappearance of symptoms. Docetaxel infusion was, thereafter, completed. With moderate symptoms, such as generalised pruritus, dyspnoea or hypotension (blood pressure still above 80 mmHg), the infusion of docetaxel was to be halted and antihistamines and i.v. corticosteroids were to be given. The docetaxel infusion was to be resumed after disappearance of symptoms. Premedication with corticosteroids and antihistamines was then optional in the subsequent course of treatment. Bronchospasms, generalised urticaria, hypotension with a systolic blood pressure of less than 80 mmHg and angio-oedema were considered severe symptoms, and if these occurred the docetaxel infusion was stopped and antihistamines and steroids given. If possible, the docetaxel infusion was resumed within 3 h after the patient recovered and in this case premedication was mandatory. Premedication was also necessary with subsequent cycles and comprised dexchlorpheniramine i.v. 5-1O mg and orally 5 mg and dexamethasone 5-10 mg i.v. and orally 20 mg, within 1 h before treatment.
In the case of grade 1 cutaneous reactions, according the NCI common toxicity criteria, no dose modification resulted. If grade 2 cutaneous reactions were observed, the subsequent dose was reduced by 25%; in the case of grade 3 toxicity, retreatment was delayed 1 week and then a dose modification had to be applied.
Resuts
Forty-three patients were enrolled in the trial between May and August 1992, 37 being eligible and evaluable for analysis.
Reasons for non-eligibility were: non-measurable lesions (three patients), SCLC (one patient) and unstable cardiovascular disease (one patient). In addition one patient was never treated and had pre-existing significant neuropathy. There were 28 male and nine female patients with a median age of 57 Reasons for withdrawal from the study were disease progression in 18 patients, toxicity in seven (fluid retention in two, hypersensitivity in two, asthenia in one, paraesthesia and arthralgia in one, venous thrombosis at the injection site in one), patient refusal in three, end of protocol in six, intercurrent death in five.
Haematological toxicity (see Table II ) Significant leucopenia was found in 87% of the cycles and neutropenia in 95% of the cycles, being CTC grade 3 and 4 in 62%. Febrile neutropenia occurred in nine cycles (5%); proven infections were only seen in 4% of the cycles, while on patient died from a neutropenia-related septicaemia. Thrombocytopenia and anaemia, when they occurred, were only mild. Tables III and IV) Complete hair loss occurred universally in all patients receiving two or more cycles. Skin toxicity was also common (65%), but usually of mild to moderate severity. Symptoms included pruritus, dry skin, erythema and desquamation. Furthermore, nail changes consisting of calcification and/or onycholysis were found in 22% of patients. Asthenia, malaise and fatigue were encountered in 57% of the patients, and diarrhoea in 13% of cycles. Weight gain, oedema and pleural Local phlebitis was found in 8%.
Non-haematological toxicity (see
Neurological side-effects (38%), usually sensory neurotoxicity (35%), were mostly mild and the symptoms are shown in Table V . Pulmonary symptoms occurred in 30% of the patients, but they were related to fluid retention or hypersensitivity. CTC grade 3 and 4 pulmonary symptoms were found in 8% of patients. Other toxicities only occurred infrequently.
Responses (see Table VI (Rigas et al., 1993) . Paclitaxel (Taxol) has also been found to be active in non-small-cell lung cancer with a response rate of 22% (Donehower & Rowinsky, 1993) . Further follow-up is needed to determine the definitive response duration of this active and generally well-tolerated new drug. The impact of concomitant steroids on the drug profile of docetaxel (Taxoteretm) needs further evaluation.
The combination of docetaxel (Taxcoteretm4) with other active agents for treatment of NSCLC, such as cisplatin or ifosfamide, is presently under investigation.
